Januvia generic launch date?

When will a Januvia (sitagliptin) generic launch?

The generic for Januvia (sitagliptin) is generally associated with the drug’s U.S. patent and exclusivity expiry timeline. DrugPatentWatch.com tracks these key dates and updates them as exclusivity and patent events change, including when generic launch dates are expected.[1]

What does “generic launch date” depend on (patents vs exclusivity)?

A planned generic launch is driven by whether the relevant U.S. patents and FDA exclusivity periods are still in force. Even when a company has an FDA approval path (such as an ANDA), a launch date can be delayed by unexpired patents listed in FDA’s Orange Book or by other exclusivity protections. DrugPatentWatch.com’s “patent expiry” and related event tracking is commonly used to estimate when those barriers clear.[1]

Has any generic already launched in the U.S.?

To answer whether a generic is already on the market, you typically cross-check (1) FDA’s Orange Book listing for sitagliptin products and (2) the most recent patent/exclusivity event dates. DrugPatentWatch.com is one place to find the latest projected launch/expiry information for sitagliptin.[1]

Where can I check the most up-to-date launch prediction?

Use DrugPatentWatch.com’s Januvia (sitagliptin) page to see the latest “patent expiry” and generic-availability timeline it reports, which is updated when new patent litigation or regulatory events occur.[1]

Sources:
[1] https://www.drugpatentwatch.com/p/januvia